Cargando…

Development of Bevirimat (PA-457): first-in-class HIV maturation inhibitor

Detalles Bibliográficos
Autor principal:	Allaway, Graham P
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2006
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1716993/ http://dx.doi.org/10.1186/1742-4690-3-S1-S8

Ejemplares similares

Potent Activity of the HIV-1 Maturation Inhibitor Bevirimat in SCID-hu Thy/Liv Mice
por: Stoddart, Cheryl A., et al.
Publicado: (2007)

HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat
por: Fun, Axel, et al.
Publicado: (2011)

Preservation of HIV-1 Gag Helical Bundle Symmetry by Bevirimat Is Central to Maturation Inhibition
por: Pak, Alexander J., et al.
Publicado: (2021)

Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1maturation inhibitor bevirimat
por: Adamson, Catherine S, et al.
Publicado: (2010)

The prototype HIV-1 maturation inhibitor, bevirimat, binds to the CA-SP1 cleavage site in immature Gag particles
por: Nguyen, Albert T, et al.
Publicado: (2011)

Predicting Bevirimat resistance of HIV-1 from genotype
por: Heider, Dominik, et al.
Publicado: (2010)

P457 Clinical correlation of beta galactomannan with culture and patient outcome in a tertiary care center in south india
por: K., Vichitra, et al.
Publicado: (2022)

HIV Gag and PR: partners in resistance to protease and maturation inhibitors
por: Nijhuis, Monique
Publicado: (2011)

Patient engagement – the PaCER model
por: Hylton, Chris
Publicado: (2015)

Coordinated changes of HIV-1 Gag and Env during assembly and maturation
por: Kräusslich, Hans-Georg
Publicado: (2013)

Improved Bevirimat resistance prediction by combination of structural and sequence-based classifiers
por: Dybowski, J Nikolaj, et al.
Publicado: (2011)

New Phosphorus Analogs of Bevirimat: Synthesis, Evaluation of Anti-HIV-1 Activity and Molecular Docking Study
por: Chrobak, Elwira, et al.
Publicado: (2019)

LEDGINs, a novel class of antivirals targeting HIV integrase during integration and assembly
por: Debyser, Zeger
Publicado: (2013)

The actions of BAFF in B-lymphocyte maturation and its effects on the development of autoimmune disease
por: Melchers, F
Publicado: (2003)

Entry inhibitors as topical microbicides to prevent HIV-1 sexual transmission
por: Moore, John P
Publicado: (2006)

Collaborative implementation of screening, brief intervention, and referral to treatment within the medical community of Blair County, PA
por: Pringle, Janice, et al.
Publicado: (2015)

Novel resistance mechanism of HIV-1 To peptide fusion inhibitors
por: Gupta, Nidhi, et al.
Publicado: (2006)

Potent suppression of HIV viral replication by a novel inhibitor of Tat
por: Mousseau, Guillaume, et al.
Publicado: (2012)

Development of CDK inhibitors as cancer therapeutics
por: Lane, D
Publicado: (2005)

A first-in-man, double blind, placebo controlled study of the candidate therapeutic vaccine Opal-HIV-Gag(c) in HIV infected patients receiving HAART
por: Jackson, AG, et al.
Publicado: (2012)

Long-term probability of detecting drug-resistant HIV in patients starting antiretroviral therapy within the first year of HIV infection
por: Lodi, S, et al.
Publicado: (2010)

The prevalence of obesity in mature Icelandic horses in Denmark
por: Jensen, Rasmus Bovbjerg, et al.
Publicado: (2015)

S011-06 OA. HIV specific T cell responses and response patterns associated with viral control independent of classical non-progessor HLA class I alleles
por: Zuniga, R, et al.
Publicado: (2009)

Structural basis for germline gene usage of a potent class of antibodies targeting the CD4 binding site of HIV-1 gp120
por: West, AP, et al.
Publicado: (2012)

Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor
por: Harding, James J., et al.
Publicado: (2018)

Cardiovascular risk assessment in persons with HIV in the developing world: comparing three risk equations in a cohort of HIV-infected Thais
por: Edwards-Jackson, N, et al.
Publicado: (2010)

Can an initial end-tidal CO(2) <1.33 kPa predict lack of return of spontaneous circulation during pre-hospital cardiac arrest?
por: Rognås, Leif, et al.
Publicado: (2014)

Developing an implementation strategy for SBIRT in general hospital: first phase
por: Sánchez, Alejandro, et al.
Publicado: (2015)

Engineering chemokines to develop putative anti HIV-1 agents
por: Deepu, A, et al.
Publicado: (2012)

LCZ696, an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure and hypertension
por: Lefkowitz, Martin P
Publicado: (2011)

Correlation between maturation, growth spurt, and the progression of adolescent idiopathic scoliosis
por: Coillard, C, et al.
Publicado: (2013)

P485 Hiv-positive, solid organ transplant (SOT), and non-Hiv-positive/non-transplant (NHNT) associated with cryptococcosis in Brazil: First national multicenter cohort study
por: Cavassin, Francelise Bridi, et al.
Publicado: (2022)

OA05-06 LB. First-in-human Phase 1 safety and immunigenicity of an adenovirus serotype 26 HIV-1 vaccine vector
por: Baden, LR, et al.
Publicado: (2009)

Poly(ADP-ribose) polymerase inhibitor development: are we in the right direction?
por: Plummer, R
Publicado: (2011)

Activity of the integrase inhibitor S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: week 24 results of the VIKING study (ING112961)
por: Eron, J, et al.
Publicado: (2010)

Successions: (art. 457-640 CC)
por: Guinand, Jean, et al.
Publicado: (1992)

Successions: (art. 457-640 CC)
por: Guinand, Jean, et al.
Publicado: (1999)

A18 INTERKINGDOM DYNAMICS AND NUTRITION ARE ASSOCIATED WITH DIVERGENT MATURATIONAL PATTERNS OF THE INFANT BACTERIAL AND FUNGAL GUT MICROBIOME
por: Mercer, E, et al.
Publicado: (2023)

An unprecedented and simple gp120 switch mechanism enables HIV-1 to overcome multiple entry inhibitors and tropism limitations
por: Platt, Emily, et al.
Publicado: (2006)

Two year persistent treatment effect in reducing nasal symptoms of cat allergy after 4 doses of Cat-PAD, the first in a new class of synthetic peptide immuno-regulatory epitopes
por: Hafner, Roderick, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_rg7sei2kit8s8gunelg0ikuv1t